Shared Decision Making With Breast Cancer Patients
Launched by VEJLE HOSPITAL · Nov 25, 2019
Trial Information
Current as of August 28, 2025
Completed
Keywords
ClinConnect Summary
The risk of recurrence of breast cancer is lowered by adjuvant medical treatment as well as by radiotherapy (RT). On the other hand, all adjuvant treatments involve a risk of side effects; some are acute and transient while others are long-term. Considering the well-known side effects of irradiation, it seems appropriate to involve patients in the decision on whether to receive irradiation.
In the shared decision making (SDM) process clinicians and patients work together to make appropriate health decisions based on clinical evidence and the patient's informed preferences. A patient decisi...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Histologically verified breast cancer or ductal carcinoma in situ breast cancer
- • Candidate for adjuvant radiotherapy Danish Breast Cancer Group type F after breast-conserving surgery for T1-2, N0-Nmi, M0 disease according to national guidelines.
- • Signed confirmation of participation.
- Exclusion Criteria:
- • Bilateral breast cancer or suspicion of disseminated cancer
- • Unable to understand the information, the planned treatment or follow-up for any reason.
- • Earlier radiotherapy towards the thoracic region.
About Vejle Hospital
Vejle Hospital is a leading healthcare institution in Denmark, dedicated to advancing medical research and enhancing patient care through innovative clinical trials. With a focus on multidisciplinary collaboration, Vejle Hospital leverages its state-of-the-art facilities and experienced research teams to conduct rigorous studies across various therapeutic areas. Committed to ethical standards and patient safety, the hospital aims to contribute valuable insights to the medical community, ultimately improving treatment outcomes and healthcare practices. Through its clinical trial initiatives, Vejle Hospital strives to foster a culture of scientific excellence and drive advancements in health and medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Odense, , Denmark
Copenhagen, , Denmark
Aarhus, , Denmark
Aalborg, , Denmark
Vejle, , Denmark
Herlev, , Denmark
Næstved, , Denmark
Patients applied
Trial Officials
Karina D Steffensen, Professor
Study Chair
Vejle Hospital
Stine R Sondergaard, M.D.
Principal Investigator
Vejle Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials